Abstract
Radiogenomic signatures associated with genomic assays (Oncotype DX) were identified as independent predictors after adjusting for clinical factors for survival and neoadjuvant chemotherapy response in estrogen receptor–positive breast cancer.
Original language | English (US) |
---|---|
Journal | Radiology |
DOIs | |
State | Published - Nov 30 2021 |
Bibliographical note
KAUST Repository Item: Exported on 2021-12-14ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging